Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

BACKGROUND: We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified. METHODS: Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1, and PD-...

Descripción completa

Detalles Bibliográficos
Autores principales: Giraldo, Nicolas A., Nguyen, Peter, Engle, Elizabeth L., Kaunitz, Genevieve J., Cottrell, Tricia R., Berry, Sneha, Green, Benjamin, Soni, Abha, Cuda, Jonathan D., Stein, Julie E., Sunshine, Joel C., Succaria, Farah, Xu, Haiying, Ogurtsova, Aleksandra, Danilova, Ludmila, Church, Candice D., Miller, Natalie J., Fling, Steve, Lundgren, Lisa, Ramchurren, Nirasha, Yearley, Jennifer H., Lipson, Evan J., Cheever, Mac, Anders, Robert A., Nghiem, Paul T., Topalian, Suzanne L., Taube, Janis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167897/
https://www.ncbi.nlm.nih.gov/pubmed/30285852
http://dx.doi.org/10.1186/s40425-018-0404-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167897/
https://www.ncbi.nlm.nih.gov/pubmed/30285852
http://dx.doi.org/10.1186/s40425-018-0404-0

Ejemplares similares